Your browser doesn't support javascript.
loading
Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant Glioma.
Ruiz-Rodado, Victor; Seki, Tomohiro; Dowdy, Tyrone; Lita, Adrian; Zhang, Meili; Han, Sue; Yang, Chunzhang; Cherukuri, Murali K; Gilbert, Mark R; Larion, Mioara.
Afiliação
  • Ruiz-Rodado V; Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA.
  • Seki T; Radiation Biology Branch, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA.
  • Dowdy T; Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA.
  • Lita A; Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA.
  • Zhang M; Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA.
  • Han S; Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA.
  • Yang C; Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA.
  • Cherukuri MK; Radiation Biology Branch, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA.
  • Gilbert MR; Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA.
  • Larion M; Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA.
Cancers (Basel) ; 12(6)2020 Jun 19.
Article em En | MEDLINE | ID: mdl-32575619
ABSTRACT
Understanding the metabolic reprogramming of aggressive brain tumors has potential applications for therapeutics as well as imaging biomarkers. However, little is known about the nutrient requirements of isocitrate dehydrogenase 1 (IDH1) mutant gliomas. The IDH1 mutation involves the acquisition of a neomorphic enzymatic activity which generates D-2-hydroxyglutarate from α-ketoglutarate. In order to gain insight into the metabolism of these malignant brain tumors, we conducted metabolic profiling of the orthotopic tumor and the contralateral regions for the mouse model of IDH1 mutant glioma; as well as to examine the utilization of glucose and glutamine in supplying major metabolic pathways such as glycolysis and tricarboxylic acid (TCA). We also revealed that the main substrate of 2-hydroxyglutarate is glutamine in this model, and how this re-routing impairs its utilization in the TCA. Our 13C tracing analysis, along with hyperpolarized magnetic resonance experiments, revealed an active glycolytic pathway similar in both regions (tumor and contralateral) of the brain. Therefore, we describe the reprogramming of the central carbon metabolism associated with the IDH1 mutation in a genetically engineered mouse model which reflects the tumor biology encountered in glioma patients.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2020 Tipo de documento: Article